Clinical trial
Long-term Follow-up on Immunogenicity & Safety of…
NCT00406211 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00406211 |
|---|---|
| Title | Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine |
| Official title | Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rubella, Varicella, Mumps, Measles |
| Intervention type | Biological |
| Interventions | MMRV, MMR (Priorix®), Varicella (Varilrix®) |
| Enrollment | 398 |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Dec 4, 2006 |
| Last update posted | Sep 15, 2016 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: